Altered intracellular signaling by imatinib increases the anti‐cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells

Tyrosine kinase inhibitors (TKI), including imatinib (IM), improve the outcome of CML therapy. However, TKI treatment is long‐term and can induce resistance to TKI, which often leads to a poor clinical outcome in CML patients. Here, we examined the effect of continuous IM exposure on intracellular e...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirao, Takuya, Yamaguchi, Masashi, Kikuya, Megumi, Chibana, Hiroji, Ito, Kousei, Aoki, Shigeki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765287/
https://www.ncbi.nlm.nih.gov/pubmed/29121435
http://dx.doi.org/10.1111/cas.13442

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765287/
https://www.ncbi.nlm.nih.gov/pubmed/29121435
http://dx.doi.org/10.1111/cas.13442

Ejemplares similares